迈克生物(300463) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥676,400,369.15, a decrease of 26.85% compared to ¥924,725,004.03 in the same period last year[6] - Net profit attributable to shareholders was ¥116,873,753.42, down 42.10% from ¥201,843,094.15 year-on-year[6] - The company's basic earnings per share decreased by 43.87% to ¥0.1908 from ¥0.3399 in the same period last year[6] - The net profit for the current period is CNY 117,826,419.32, a decrease of 44.4% compared to CNY 212,187,393.54 in the previous period[34] - The total profit for the current period is CNY 135,041,876.58, down from CNY 248,718,876.40, representing a decline of 45.3%[34] - The operating profit for the current period is CNY 140,309,024.10, compared to CNY 250,526,631.03 in the previous period, reflecting a decrease of 44%[34] - The total comprehensive income for the current period is CNY 109,493,201.32, down from CNY 212,187,393.54 in the previous period, a decline of 48.3%[34] Cash Flow - The net cash flow from operating activities increased by 39.08% to ¥167,046,659.56, compared to ¥120,108,068.54 in the previous year[12] - The cash flow from operating activities for the current period is CNY 167,046,659.56, an increase of 39.1% from CNY 120,108,068.54 in the previous period[39] - The company’s investment activities generated a net cash flow of ¥31,799,722.54, a 102.97% increase compared to a net outflow of ¥1,070,469,152.48 in the previous year[12] - The cash inflow from investment activities is CNY 706,876,521.14, while cash outflow is CNY 675,076,798.60, resulting in a net cash flow of CNY 31,799,722.54[41] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥8,270,656,198.29, reflecting a 1.33% increase from ¥8,161,865,314.41 at the end of the previous year[6] - Total assets as of March 31, 2023, amounted to CNY 8,270,656,198.29, up from CNY 8,168,239,295.99, indicating a growth of approximately 1.25%[30] - Total liabilities decreased slightly to CNY 1,631,911,191.11 from CNY 1,638,987,490.13, a reduction of about 0.4%[27] - The company's equity attributable to shareholders increased to CNY 6,401,572,687.34 from CNY 6,293,032,151.92, reflecting a growth of approximately 1.7%[30] Research and Development - Research and development expenses rose by 25.80% to ¥58,345,527.09, up from ¥46,379,511.10 in the same period last year[12] - Research and development expenses for Q1 2023 were CNY 58,345,527.09, up from CNY 46,379,511.10, indicating an increase of approximately 25.8%[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 42,002, with the largest shareholder, Tang Yong, holding 11.11% of shares, amounting to 68,062,301 shares[16] - The largest shareholder, Wang Dengming, holds 7.43% of shares, amounting to 45,534,495 shares[16] - The total number of restricted shares at the beginning of the period was 117,119,807, with no shares released or added during the period, maintaining the same total[19] - The company reported a total of 51,046,726 restricted shares held by Tang Yong, which remain locked due to executive restrictions[19] - The company has a total of 117,119,807 restricted shares, all of which are subject to lock-up agreements[19] - The company has no new shares added to the restricted category during the reporting period[19] Project Updates - The company has extended the completion date for the "Mike Bio Tianfu International Bio City IVD Industrial Park Project" to the end of December 2024, based on prudent principles and actual project progress[20] - The company’s independent directors agreed that the project extension aligns with the company's operational needs and long-term development plans[20] Other Financial Metrics - The weighted average return on equity decreased to 1.84%, down from 4.59% in the same period last year[6] - The company experienced a 54.40% decrease in notes receivable, which fell to ¥17,937,900.02 from ¥39,335,042.95[12] - Deferred tax assets increased from 154,968,997.84 RMB to 161,342,979.42 RMB, reflecting an adjustment of 6,373,981.58 RMB due to the implementation of new accounting standards[20] - The total assets increased from 8,161,865,314.41 RMB to 8,168,239,295.99 RMB, with an adjustment of 6,373,981.58 RMB[20] - Inventory levels increased to CNY 1,125,736,819.18 from CNY 1,039,480,640.38, marking an increase of about 8.3%[24] - The company reported a decrease in short-term borrowings to CNY 233,822,506.34 from CNY 248,075,777.91, a reduction of about 5.7%[27] - The company reported a decrease in other comprehensive income after tax of CNY -8,333,218.00 for the current period[34] - The company has not undergone an audit for the first quarter report[43]